TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9327317
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg orally before surgery and once daily postoperatively
Study: 4003987
Drug: Intramuscular recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular recombinant interferon alpha‐2 at dosages of 10 to 50 MU/d
Study: 4003987
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant interferon alpha‐2 at dosages of 10 to 50 MU/d
Study: 3067408
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate standard tablets (nitrosorbide-NS) at a dose of 10 mg per os
Study: 3067408
Drug: Sublingual NS
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual NS administration
Study: 3067408
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate prolonged action isomac-retard containing 40 mg
Study: 3067408
Drug: Increased NS
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased NS dose per os
Study: 29179016
Drug: Group family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group family-based cognitive behavioral therapy (GF-CBT)
Study: 25743819
Drug: EAAL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAAL treatment group
Study: 15673841
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced therapy (mCIT)
Study: 18174447
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control regimen
Study: 1320916
Drug: Alizapride (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (12 mg/kg) plus Dexamethasone (8 mg)
Study: 1320916
Drug: Metoclopramide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (7 mg/kg) plus Dexamethasone (12 mg)
Study: 6375273
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose heparin 5000 IU every 12 hours
Study: 29686818
Drug: Standard neuromotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neuromotor rehabilitation treatment
Study: 26725544
Drug: Opicapone 5
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 5 mg
Study: 3185464
Drug: Zolpidem (hypnotic)
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem (hypnotic)
Study: 30715535
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg Se from SY
Study: 30715535
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg Se from SY
Study: 30715535
Drug: 3.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg/kg Se from SY
Study: 30715535
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg Se from SY (basal diet)
Study: 27838474
Drug: Personalized AHFS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized AHFS treatments (specific treatments not detailed)
Study: 27838474
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with intravenous diuretics (control group)
Study: 15176647
Drug: A6 15
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 15 mg
Study: 15176647
Drug: A6 35
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 35 mg
Study: 15176647
Drug: A6 75
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 75 mg
Study: 15176647
Drug: A6 150
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 150 mg
Study: 15176647
Drug: A6 300
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 300 mg
Study: 15176647
Drug: A6 35
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 35 mg repeated doses
Study: 15176647
Drug: A6 75
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 75 mg repeated doses
Study: 15176647
Drug: A6 150
Normalized name: Chlorin a6
DrugBank: Phytochlorin (DB19265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A6 150 mg repeated doses
Study: 11533546
Drug: Intravenous liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous liposomal amphotericine B + oral itraconazole
Study: 12122510
Drug: Intravenous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous fluconazole + oral itraconazole
Study: 9793313
Drug: Prednisone 40
Normalized name: prednisone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 40 mg/day
Study: 31595803
Drug: Medication usage
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication usage recorded as a treatment for nausea AEs (76% of cases)
Study: 29578944
Drug: PF‐05089771 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF‐05089771 150 mg twice daily
Study: 30136102
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg twice daily
Study: 28424870
Drug: Concurrent high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent high-intensity interval training (CT)
Study: 15657474
Drug: CAF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (5 mg/kg)
Study: 15657474
Drug: CAF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (3 mg/kg)
Study: 15657474
Drug: CAF (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAF (7 mg/kg)
Study: 2082718
Drug: Dydrogesterone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (20 mg/day during the last 12 days of the menstrual cycle)
Study: 299221
Drug: Chemo-Immunotherapy consisting
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-Immunotherapy consisting of 5-Fluorouracil and CCNU and Corynebacterium parvum administered intermittently for one year.
Study: 31782768
Drug: 9 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 × 105 PfSPZ Vaccine
Study: 31782768
Drug: 1.8 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 × 106 PfSPZ Vaccine
Study: 26179504
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg three times per day for 3 days before surgery)
Study: 17906207
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m2 during 24 hours (arm 1)
Study: 17906207
Drug: Paclitaxel 120
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 120 mg/m2 during 96 hours (arm 2)
Study: 8703860
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm treatment
Study: 8703860
Drug: 5 mm
Normalized name: SUR-FIT 45 mm Wafer, Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm treatment
Study: 8703860
Drug: Multizone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multizone treatment
Study: 31686109
Drug: Adjuvanted recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted recombinant glycoprotein E herpes zoster vaccine
Study: 26657263
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection with betamethasone
Study: 21508180
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg 3 times daily with quinidine 100 mg twice daily
Study: 21508180
Drug: Propafenone 150
Normalized name: propafenone 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 150 mg 3 times daily with placebo
Study: 12511809
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (buspirone or fluoxetine)
Study: 7622822
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) in placebo controlled trials
Study: 7622822
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants (TCAs) in placebo controlled trials
Study: 379932
Drug: Levamisole as
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole as adjunctive treatment between cycles of chemotherapy
Study: 379932
Drug: Conventional high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional high dose chemotherapy
Study: 31887090
Drug: AB‐ace (alfaxalone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB‐ace (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with acepromazine [0.02 mg/kg])
Study: 31887090
Drug: AB‐mid (alfaxalone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB‐mid (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with midazolam [0.2 mg/kg])
Study: 31887090
Drug: AB‐dex (alfaxalone
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB‐dex (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with dexmedetomidine [0.005 mg/kg])
Study: 31438618
Drug: Rifaximin for
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin for 10 days followed by nutraceutical agent (G1)
Study: 25222572
Drug: Fish aquarium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish aquarium animal‐assisted therapy (FA‐AAT)
Study: 21102369
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine
Study: 15085492
Drug: Poractant alfa
Normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Poractant alfa (Curosurf) 100 mg/kg
Study: 15085492
Drug: Poractant alfa
Normalized name: Poractant alfa
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Poractant alfa (Curosurf) 200 mg/kg
Study: 15085492
Drug: Beractant (Survanta)
Normalized name: Beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beractant (Survanta) 100 mg/kg
Study: 11420324
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg ketamine
Study: 10322818
Drug: IKPA tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: IKPA tablets and inhalated BDP
Study: 29773516
Drug: Lymphoedema management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoedema management package including instructions for foot hygiene, skin care, bandaging, exercises, and use of socks and shoes, supported by lay Community Podoconiosis Agents at monthly meetings.
Study: 27073044
Drug: Topical liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposomal azithromycin administered twice daily
Study: 27073044
Drug: Intralesional meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional meglumine antimoniate (glucantime) administered weekly with a volume of 0.5-2 cm3 into each lesion
Study: 22342850
Drug: Dual-antiplatelet therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-antiplatelet therapy with aspirin and clopidogrel
Study: 22342850
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with OAC, aspirin, and clopidogrel
Study: 29447773
Drug: OAC plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC plus aspirin
Study: 22342850
Drug: OAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC with either 1 or 2 antiplatelet agents
Study: 15290154
Drug: Anecortave Acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave (DB12081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anecortave Acetate for Depot Suspension (3, 15 and 30 mg)
Study: 7492378
Drug: Surgery for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery for cure followed by postoperative chemotherapy (CAV - cyclophosphamide, doxorubicin, vincristine)
Study: 2182696
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg sustained-release theophylline (morning and evening)
Study: 2182696
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg sustained-release theophylline (two capsules morning and evening)
Study: 2182696
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules morning and evening)
Study: 1096539
Drug: Unilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral ECT treatment
Study: 1096539
Drug: Bilateral ECT
Normalized name: ECT-001 expanded cord blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ECT treatment
Study: 15126259
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (CT)
Study: 22338468
Drug: Procalcitonin-guided antibiotic
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided antibiotic treatment (PCT-group; n = 102)
Study: 16682147
Drug: Androgen suppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen suppression therapy (AST) administered at a PSA level of approximately 10 ng/mL
Study: 14745141
Drug: Intravenous atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous atrial natriuretic peptide (ANP) administration
Study: 7962387
Drug: Method C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method C: no further treatment with the Percoll gradient
Study: 3297471
Drug: Insulin (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.15 unit/kg body weight)
Study: 23676766
Drug: 0.1 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 µg rESAT6
Study: 23676766
Drug: 0.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg rESAT6
Study: 23676766
Drug: 1 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg rESAT6
Study: 20951320
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitor administration in poor responders
Study: 20951320
Drug: Poor response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Poor response to aspirin
Study: 16945048
Drug: Heparin flushes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flushes (3 ml of porcine heparin 100 U/ml, 300 U per catheter lumen at least once/day)
Study: 16945048
Drug: Lepirudin flushes
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lepirudin flushes (3 ml of lepirudin 100 microg/ml, 300 microg per catheter lumen at least once/day)
Study: 11315234
Drug: Tiludronate 50
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 50 mg/day
Study: 8216439
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) spray preparation (Isoket Spray) 2.5 mg per valve release
Study: 8216439
Drug: Reference spray
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference spray preparation
Study: 8216439
Drug: Isosorbide-2-mononitrate (IS-2-MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-2-mononitrate (IS-2-MN) from test spray
Study: 8216439
Drug: Isosorbide-2-mononitrate (IS-2-MN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-2-mononitrate (IS-2-MN) from reference spray
Study: 8216439
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) from test spray
Study: 8216439
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) from reference spray
Study: 2890019
Drug: Post-treatment Campylobacter
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment Campylobacter pylori status
Study: 28380313
Drug: Cholesterol-lowering medication
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering medication (CLM) during endocrine therapy
Study: 21209140
Drug: Clinical pharmacist
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist service (medication reviews, feedback to physicians, drug treatment discussions, medication reports)
Study: 19128534
Drug: Cognitive-motor dual-tasking
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-motor dual-tasking training program (5 weeks, twice-daily practice)
Study: 25542604
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment
Study: 2905808
Drug: Lormetazepam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.02 mg/kg) followed by Ro 15‐1788 (0.03 mg/kg)
Study: 2905808
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.03 mg/kg) alone
Study: 2905808
Drug: Lormetazepam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.02 mg/kg)
Study: 2905808
Drug: Ro 15‐1788
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15‐1788 (0.03 mg/kg)
Study: 2905808
Drug: Lormetazepam group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam group prior to administration
Study: 30193927
Drug: LE gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: LE gel 2 times a day
Study: 30193927
Drug: LE gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: LE gel 3 times a day
Study: 27349272
Drug: Intrathecal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dexmedetomidine (5 µg)
Study: 27349272
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (100 µg)
Study: 22537244
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of chocolate (70% cocoa) daily (Group A)
Study: 19915454
Drug: Quetiapine 50
Normalized name: quetiapine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 50 mg every 12 hrs, increased as needed up to 200 mg every 12 hrs
Study: 10947303
Drug: Thymoglobulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (1.5 mg/kg/day for an average of 10 days)
Study: 10947303
Drug: Atgam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atgam (15 mg/kg/day for an average of 9.7 days)
Study: 2004962
Drug: Simulated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated with oral contrast
Study: 2004962
Drug: Simulated without
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated without oral contrast
Study: 30935524
Drug: Melatonin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (high dose [24 mg], sustained-release formulation)
Study: 29454227
Drug: l-Carnitine 2g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Carnitine 2g/day for one week
Study: 25070319
Drug: Metreleptin (0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metreleptin (0.06 to 0.24 mg/kg/d) for 6 months to 11 years
Study: 23278572
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg EN101
Study: 23278572
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg EN101
Study: 23278572
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg EN101
Study: 8732611
Drug: Intravenous thiopentone
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiopentone (group I)
Study: 8732611
Drug: Halothane inhalation
Normalized name: Halothane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane inhalation (group II)
Study: 8732611
Drug: Rectal methohexitone
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal methohexitone (group III)
Study: 6214438
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg desogestrel + 0.050 mg ethinylestradiol
Study: 6214438
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol
Study: 31357887
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg and ezetimibe 10 mg fixed-dose combination
Study: 17962426
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination
Study: 24692082
Drug: Neoadjuvant letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant letrozole (LET) administered for 24-28 weeks before surgery
Study: 17471547
Drug: Creatine supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplements (20 gm/day for 8 days, then 3 gm/day)
Study: 17471547
Drug: Creatine supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplements
Study: 10822073
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and aspirin (group 1)
Study: 10822073
Drug: Argatroban and
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban and aspirin (group 2)
Study: 1639946
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin (2.5 mg, orally) during the daytime (n = 6)
Study: 1639946
Drug: Suppression of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppression of endogenous nocturnal melatonin secretion by atenolol (100 mg; n = 6)
Study: 1639946
Drug: Daytime melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime melatonin administration